BioPharma CreditLSE:BPCR +0.63%49 PEG Ratio is 28.07 as of Jul. 02, 2026, which is 33% below its 10-year median of 41.74. GuruFocus rates LSE:BPCR with a GF Score™ of 49/100 and a GF Value™ of $0.97 (Fairly Valued). The stock has 2 warning signs investors should review. Among 495 Asset Management companies, BioPharma Credit ranks worse than 94.55% on this metric.
PE Ratio without NRI / 5-Year Book Value Growth Rate*
* The 5-Year Book Value Growth Rate is the 5-year average Book Value per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for BioPharma Credit's PEG Ratio or its related term are showing as below:
LSE:BPCR'
s PEG Ratio Range Over the Past 10 Years
Min: 27.9 Med: 41.74 Max: 45.4
Current: 28.07
During the past 9 years, BioPharma Credit's highest PEG Ratio was 45.40. The lowest was 27.90. And the median was 41.74.
LSE:BPCR's PEG Ratio is ranked worse than 94.55% of 495
companies
in the Asset Management industry
Industry Median: 1.72
vs LSE:BPCR: 28.07
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
BioPharma Credit (LSE:BPCR) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
BioPharma Credit PEG Ratio Related Terms
BioPharma Credit PEG Ratio Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, BioPharma Credit's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit PEG Ratio vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's PEG Ratio distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year Book Value Growth Rate is the 5-year average Book Value per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
BioPharma Credit (LSE:BPCR) has a PEG Ratio of 28.07 as of Jul. 02, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on BioPharma Credit and its competitors. This is 33% below median its historical median of 41.74. Over the past decade, BioPharma Credit's PEG Ratio has ranged from 27.90 to 45.40. According to the industry distribution chart, BioPharma Credit ranks #468 out of 495 companies in the Asset Management industry, placing it in the top 94.5%.
Is BioPharma Credit's PEG Ratio too high?
BioPharma Credit's current PEG Ratio of 28.07 is 33% below median its 10-year median of 41.74. Over the past 10 years, this metric has ranged from a low of 27.90 to a high of 45.40. The Asset Management industry median PEG Ratio is 1.72. BioPharma Credit's value of 28.07 is 1532% above this industry median. Based on the distribution chart, BioPharma Credit ranks #468 out of 495 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, BioPharma Credit has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's PEG Ratio compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #468 out of 495 companies for PEG Ratio. This places BioPharma Credit in the lower half of its industry. The industry median PEG Ratio is 1.72. BioPharma Credit's value of 28.07 is 1532% above this benchmark. Historically, BioPharma Credit's own PEG Ratio has ranged from 27.90 to 45.40 over the past decade. While the company's 10-year median is 41.74 vs. the industry median of 1.72, BioPharma Credit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for an Asset Management company?
The median PEG Ratio among Asset Management companies is 1.72, based on 495 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current PEG Ratio of 28.07 is 1532% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on BioPharma Credit and its competitors. For the Asset Management industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current PEG Ratio is 28.07, which is 33% below median its own 10-year median of 41.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.96 — trading 1% below its estimated fair value. The current PEG Ratio is 28.07, which is 33% below median its 10-year median of 41.74 and 1532% above the Asset Management industry median of 1.72. BioPharma Credit's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current PEG Ratio is 28.07 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued.
The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
PEG Ratio: 28.07 (33% below median its 10-year median of 41.74)
GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
Industry Position: 1532% above the Asset Management median (#468 of 495)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score
Get the complete analysis for LSE:BPCR
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
